Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379282067> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W4379282067 endingPage "e15136" @default.
- W4379282067 startingPage "e15136" @default.
- W4379282067 abstract "e15136 Background: Ectonucleotide pyrophosphatase/phosphodiesterase I (ENPP1) is a type II transmembrane glycoprotein with nucleotide pyrophosphatase and phosphodiesterase enzymatic activities. Inhibiting ENPP1 activity has emerged as an attractive approach in cancer immunotherapy, based on two distinct mechanisms. One mechanism is the stabilization of cyclic GMP–AMP (2’3’-cGAMP), which binds to stimulator of IFN genes (STING) and functions as an endogenous second messenger to activate the innate immune system; the other is the lowering of adenosine concentrations in the tumor microenvironment. ENPP1 inhibitors have shown promising monotherapy activity and synergy with various targeted therapies in preclinical models. Methods: OC-1 was characterized, for activity and selectivity, in the following in vitro assays: a luminescence-based enzymatic assay; cell proliferation assays; selectivity assays against 15 phosphodiesterases (PDE) based on inhibition of enzymatic activity; and a cytokine release assay in human THP cells and mouse splenocytes looking at changes in IFN-β/CXCL10. Oral bioavailability of OC-1 in mice and rats was studied following oral gavage. Plasma exposures were quantified using standard LC/MS/MS methods. In vivo tumor growth inhibition (TGI) of OC-1 was evaluated in syngeneic mouse tumor models (CT26 and MC38), as monotherapy and in combination with an anti-PD1 antibody. OC-1 was dosed orally in all in-vivo models. Results: We have discovered a novel small molecule inhibitor of ENPP1, OC-1, with a Ki value less than 10 nM in an ENPP1 enzymatic assay. Increase in gene expression of IFN-β and CXCL10/IP10 was observed in OC-1-treated THP1 cells. No inhibition in cell proliferation in various cancer lines was seen up to the highest concentration tested (30 µM). OC-1 was also selective against 15 PDEs with IC 50 > 30 µM. The mean oral bioavailability of OC-1 was 72% and 63% in mice and rats, respectively. OC-1 showed single agent activity (20 – 40% TGI) and combination activity of approximately 75% TGI when it was combined with an anti-PD-1 antibody in in vivo efficacy studies with no impact on body weight. Conclusions: In summary, OC-1 is an orally bioavailable ENPP1 inhibitor with promising anti-tumor activity in preclinical models. Its physicochemical properties make it a suitable candidate for clinical investigation." @default.
- W4379282067 created "2023-06-05" @default.
- W4379282067 creator A5039390366 @default.
- W4379282067 creator A5039969092 @default.
- W4379282067 creator A5063015158 @default.
- W4379282067 creator A5071012377 @default.
- W4379282067 creator A5076563808 @default.
- W4379282067 creator A5078030039 @default.
- W4379282067 creator A5092083449 @default.
- W4379282067 date "2023-06-01" @default.
- W4379282067 modified "2023-10-11" @default.
- W4379282067 title "A novel orally bioavailable small molecular ENPP1 inhibitor (OC-1) for cancer immunotherapy." @default.
- W4379282067 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e15136" @default.
- W4379282067 hasPublicationYear "2023" @default.
- W4379282067 type Work @default.
- W4379282067 citedByCount "0" @default.
- W4379282067 crossrefType "journal-article" @default.
- W4379282067 hasAuthorship W4379282067A5039390366 @default.
- W4379282067 hasAuthorship W4379282067A5039969092 @default.
- W4379282067 hasAuthorship W4379282067A5063015158 @default.
- W4379282067 hasAuthorship W4379282067A5071012377 @default.
- W4379282067 hasAuthorship W4379282067A5076563808 @default.
- W4379282067 hasAuthorship W4379282067A5078030039 @default.
- W4379282067 hasAuthorship W4379282067A5092083449 @default.
- W4379282067 hasConcept C121608353 @default.
- W4379282067 hasConcept C126322002 @default.
- W4379282067 hasConcept C13373296 @default.
- W4379282067 hasConcept C136449434 @default.
- W4379282067 hasConcept C150903083 @default.
- W4379282067 hasConcept C181199279 @default.
- W4379282067 hasConcept C185592680 @default.
- W4379282067 hasConcept C189976730 @default.
- W4379282067 hasConcept C202751555 @default.
- W4379282067 hasConcept C203014093 @default.
- W4379282067 hasConcept C207001950 @default.
- W4379282067 hasConcept C2777349159 @default.
- W4379282067 hasConcept C2777701055 @default.
- W4379282067 hasConcept C2780674031 @default.
- W4379282067 hasConcept C55493867 @default.
- W4379282067 hasConcept C5858377 @default.
- W4379282067 hasConcept C62826618 @default.
- W4379282067 hasConcept C71924100 @default.
- W4379282067 hasConcept C86803240 @default.
- W4379282067 hasConcept C8891405 @default.
- W4379282067 hasConcept C96232424 @default.
- W4379282067 hasConcept C98274493 @default.
- W4379282067 hasConceptScore W4379282067C121608353 @default.
- W4379282067 hasConceptScore W4379282067C126322002 @default.
- W4379282067 hasConceptScore W4379282067C13373296 @default.
- W4379282067 hasConceptScore W4379282067C136449434 @default.
- W4379282067 hasConceptScore W4379282067C150903083 @default.
- W4379282067 hasConceptScore W4379282067C181199279 @default.
- W4379282067 hasConceptScore W4379282067C185592680 @default.
- W4379282067 hasConceptScore W4379282067C189976730 @default.
- W4379282067 hasConceptScore W4379282067C202751555 @default.
- W4379282067 hasConceptScore W4379282067C203014093 @default.
- W4379282067 hasConceptScore W4379282067C207001950 @default.
- W4379282067 hasConceptScore W4379282067C2777349159 @default.
- W4379282067 hasConceptScore W4379282067C2777701055 @default.
- W4379282067 hasConceptScore W4379282067C2780674031 @default.
- W4379282067 hasConceptScore W4379282067C55493867 @default.
- W4379282067 hasConceptScore W4379282067C5858377 @default.
- W4379282067 hasConceptScore W4379282067C62826618 @default.
- W4379282067 hasConceptScore W4379282067C71924100 @default.
- W4379282067 hasConceptScore W4379282067C86803240 @default.
- W4379282067 hasConceptScore W4379282067C8891405 @default.
- W4379282067 hasConceptScore W4379282067C96232424 @default.
- W4379282067 hasConceptScore W4379282067C98274493 @default.
- W4379282067 hasIssue "16_suppl" @default.
- W4379282067 hasLocation W43792820671 @default.
- W4379282067 hasOpenAccess W4379282067 @default.
- W4379282067 hasPrimaryLocation W43792820671 @default.
- W4379282067 hasRelatedWork W2922049377 @default.
- W4379282067 hasRelatedWork W2972054277 @default.
- W4379282067 hasRelatedWork W2982520686 @default.
- W4379282067 hasRelatedWork W4200420906 @default.
- W4379282067 hasRelatedWork W4200435310 @default.
- W4379282067 hasRelatedWork W4306252020 @default.
- W4379282067 hasRelatedWork W4308402608 @default.
- W4379282067 hasRelatedWork W4362597326 @default.
- W4379282067 hasRelatedWork W4366463631 @default.
- W4379282067 hasRelatedWork W4376617805 @default.
- W4379282067 hasVolume "41" @default.
- W4379282067 isParatext "false" @default.
- W4379282067 isRetracted "false" @default.
- W4379282067 workType "article" @default.